Definium Therapeutics advances Phase 3 trials for DT120 in major depressive disorder and anxiety

Definium Therapeutics advances Phase 3 trials for DT120 in major depressive disorder and anxiety
Definium shares DT120 trial update

Definium Therapeutics announced that Chief Medical Officer Dan Karlin presented new information on the company’s Phase 3 studies evaluating DT120 for major depressive disorder and generalized anxiety at the European College of Neuropsychopharmacology Congress.

The presentation, part of the Novel Therapies Symposium, centered on progress and insights from these pivotal clinical trials, signaling continued development of DT120 as a potential therapy for mental health conditions. No additional clinical or commercial details were shared in the tweet.

Definium Therapeutics recently won the 2026 Poster Award at PsychCongress for its Phase 3 results in anxiety disorder and updates on depression, according to a company announcement. Earlier, the company reported positive Phase 3 Panorama results for DT120 ODT in generalized anxiety disorder, marking a third key development milestone in clinical updates. These prior milestones add context to the new data presented at the ECNP Congress.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.